Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma

Heung Cheol Kim, Ki Tae Suk, Dong Joon Kim, Jai Hoon Yoon, Yeon Soo Kim, Gwang Ho Baik, Jin Bong Kim, Chang Hoon Kim, Hotaik Sung, Jong Young Choi, Kwang Hyub Han, Seung Ha Park

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Aim: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Methods: Between January 2001 and September 2011, 129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled. Patient characteristics, routine computed tomography and TACE findings, survival time and 1-, 5-, and 10-year survival rates, risk factors for mortality, and survival rates according to the number of risk factors were assessed. Results: The mean size of HCC tumors was 2.4 ± 1.1 cm, and the mean number of TACE procedures performed was 2.5 ± 2.1. The mean overall survival time and 1-, 5-, and 10-year survival rates were 80.6 ± 4.9 mo and 91%, 63% and 49%, respectively. In the Cox regression analysis, a Child-Pugh score > 5 (P = 0.005, OR = 3.86), presence of arterio-venous shunt (P = 0.032, OR = 4.41), amount of lipiodol used (> 7 mL; P = 0.013, OR = 3.51), and female gender (P = 0.008, OR = 3.47) were risk factors for mortality. The 1-, 5-, and 10-year survival rates according to the number of risk factors present were 96%, 87% and 87% (no risk factors), 89%, 65%, and 35% (1 risk factor), 96%, 48% and unavailable (2 risk factors), and 63%, 17%, and 0% (3 risk factors), respectively (P < 0.001). Conclusion: TACE may be used as curative-intent therapy in patients with BCLC stage 0 and stage A HCC. The Child-Pugh score, arterio-venous shunt, amount of lipiodol used, and gender were related to mortality after TACE.

Original languageEnglish
Pages (from-to)745-754
Number of pages10
JournalWorld Journal of Gastroenterology
Volume20
Issue number3
DOIs
StatePublished - 2014 Jan 28

Keywords

  • Carcinoma
  • Chemoembolization
  • Efficacy
  • Hepatocellular
  • Stage
  • Survival
  • Therapeutic

Fingerprint Dive into the research topics of 'Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Kim, H. C., Suk, K. T., Kim, D. J., Yoon, J. H., Kim, Y. S., Baik, G. H., Kim, J. B., Kim, C. H., Sung, H., Choi, J. Y., Han, K. H., & Park, S. H. (2014). Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World Journal of Gastroenterology, 20(3), 745-754. https://doi.org/10.3748/wjg.v20.i3.745